Focal Tumour Ablation: Transarterial Chemoembolization for Hepatocellular Carcinomaenglish
To provide a systematic literature review that will be one of the six components of the Recommendation Report (i.e., demand forecasting, costing analysis, jurisdictional review, literature review, system capacity, and current state) of the Focal Ablation Advisory Committee.
Patients with HCC.
Intended Guideline Users
Interventional radiologists, radiation oncologists, hepatobiliary surgeons, medical oncologists, healthcare professionals caring for patients with HCC or colorectal liver metastases.
- What is the effectiveness of transarterial chemoembolization (TACE) for the treatment of patients with hepatocellular carcinoma (HCC)?
- What is the side effect profile and treatment outcome of conventional TACE versus drug-eluting bead TACE (DEB-TACE)?
- What patient populations are most likely to benefit from TACE?
- Is there a difference in any important outcomes when performing TACE as an inpatient or an outpatient procedure?